Jamaicans suffering from pelvic-floor dysfunction or urinary incontinence could soon find relief, with the official launch of the NeoControl pelvic-floor therapy system in Jamaica.

The non-invasive treatment is being marketed by Neotonus Inc a United States-based company. Since gaining United States Food and Drug Administration (USDA) approval in 1998, more than 1.5 million NeoControl treatments have been provided in 53 countries and 46 American states.

Developed in collaboration with Emory University School of Medicine and the Georgia Institute of Technology, NeoControl uses pulsed magnetic fields to treat pelvic-floor dysfunction in men and women non-invasively, without even the need to remove the clothing.

Clinical device

According to Sydney C. Stephens, sales executive with Neotonus Inc and project manager for the Caribbean, the NeoControl therapy system is the first clinical device to use extracorporeal magnetic innervation technology for pelvic-floor muscle stimulation.

"The success of NeoControl in the United States and Europe has encouraged us to increase our presence in the global marketplace," said Neotonus' chief operating officer, Jordan Morris.

NeoControl therapy is administered in a physician's office or rehabilitation facility. Fully clothed, the patient simply sits in a comfortable armchair that has the magnetic technology embedded in the seat.

The powerful, pulsating magnetic fields, controlled by a small adjacent power unit, induce muscle contractions in the pelvic floor to build strength and endurance and increase circulation. Nothing touches the patient's skin. He or she will only feel the muscles tighten and relax as they are exercised. Patients report no pain.

Further information about NeoControl therapy is available by visiting the website www.neocontrol.com.